Compare JHS & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JHS | EDAP |
|---|---|---|
| Founded | 1973 | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 137.6M |
| IPO Year | N/A | 1997 |
| Metric | JHS | EDAP |
|---|---|---|
| Price | $11.74 | $4.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 32.8K | ★ 76.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $74,853,925.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.67 |
| P/E Ratio | $553.50 | ★ N/A |
| Revenue Growth | N/A | ★ 0.61 |
| 52 Week Low | $9.76 | $1.21 |
| 52 Week High | $11.25 | $4.29 |
| Indicator | JHS | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 66.29 |
| Support Level | $11.68 | $3.44 |
| Resistance Level | $11.83 | $4.28 |
| Average True Range (ATR) | 0.09 | 0.35 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 44.36 | 83.19 |
John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.